NovaBridge Biosciences

F:0VY

NovaBridge Biosciences

Investor Relations

I-Mab is a clinical-stage biopharmaceutical company that develops antibody-based medicines, mainly for cancer and autoimmune disease. It does not sell consumer products; its business is to discover or in-license drug candidates, run clinical trials, and work toward regulatory approval and eventual commercialization of those medicines. The company’s customers are not patients directly. Its main buyers, if its drugs succeed, are large pharmaceutical partners, hospitals, and health systems that use approved biologic medicines. I-Mab makes money through licensing deals, collaboration payments, milestones tied to drug development and approvals, and, if a product reaches the market, sales of the medicine itself. What makes I-Mab’s business different is that it sits in the high-risk, high-science part of the drug industry. It focuses on biologics, which are complex medicines made from living cells, and it relies heavily on clinical data and partnering with bigger drug companies to move candidates forward. That means its value depends on whether its experimental treatments can prove safe and effective in human trials.